MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
Ovagen Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
Ovagen is a Khavinson short-chain peptide bioregulator (Glu-Asp-Leu, EDL tripeptide) developed at the St. Petersburg Institute of Bioregulation and Gerontology by Vladimir Khavinson as the synthetic analog of the active fragment isolated from bovine liver tissue extracts. Within the cytomedin framework, EDL is hypothesized to penetrate cell and nuclear membranes through a combination of passive diffusion and PEPT1/PEPT2-mediated peptide transport, then bind short tissue-specific promoter sequences in hepatocyte DNA, upregulating albumin, transferrin, cytochrome P450 enzymes, and antioxidant response element genes including NQO1 and HO-1. Researchers study it for chronic viral hepatitis B and C with elevated transaminases, non-alcoholic fatty liver disease, drug-induced hepatotoxicity recovery in oncology supportive care, and general anti-aging stacks alongside other Khavinson peptides such as Vladonix, Endoluten, and Cerluten. Mechanistic work on EDL-type tripeptides in cultured hepatocytes shows preferential effects in cells from older animals (PMID 14523498); the Khavinson program is reviewed in PMID 21626751.
Reconstitute: Add 2 mL bacteriostatic water → 10 mg/mL concentration.
Easy measuring: At 10 mg/mL, 1 unit = 0.01 mL = 0.1 mg (100 mcg) on a U-100 insulin syringe.
Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Plasma half-life: Not formally measurable; the tripeptide is rapidly hydrolyzed in plasma. Biological effect is hypothesized to derive from a small intact fraction reaching hepatocyte nuclei.
Typical cycle: 20 to 30 day course of oral capsules at 1 to 2 capsules twice daily, repeated every 4 to 6 months in Khavinson research protocols, with interim ALT, AST, GGT, and albumin monitoring.
Regulatory status: Not approved by FDA, EMA, MHRA, or TGA. Used in Russian research contexts as a tissue-specific bioregulator; no Western randomized controlled trials exist for the isolated EDL molecule.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 2.0 mL bacteriostatic water with a sterile syringe.
Inject slowly down the vial wall; avoid foaming.
Gently swirl/roll until dissolved (do not shake).
Inject slowly; wait a few seconds before withdrawing the needle.
Do not aspirate for subcutaneous injections; inject slowly and steadily[8].
Interactive Ovagen Syringe Calculator
Currently visualizing the 20 mg vial reconstituted with 2 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 20mg dry powder in 2mL water yields 10.00 mg/mL. To evaluate a 250mcg dose, pull to 2.5 units (3 syringe ticks).
U-100 Syringe Representation
2.5 Units (3 Ticks)
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Week | Daily Dose (μg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 10 μg (0.01 mg) | 0.1 units (0.001 mL) |
| Weeks 3–4 | 20 μg (0.02 mg) | 0.2 units (0.002 mL) |
| Weeks 5–6 | 50 μg (0.05 mg) | 0.5 units (0.005 mL) |
| Weeks 7–8 | 100 μg (0.1 mg) | 1 unit (0.01 mL) |
| Weeks 9–16 | 100–150 μg (0.1–0.15 mg) | 1–1.5 units (0.01–0.015 mL) |
Administration guidelines: Refer to guidelines | 2 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 20 mg vial.
Peptide Vials (Ovagen, 20 mg each):
- check16 weeks: 1 vial (with excess remaining)
Insulin Syringes (U-100, 30-unit or 50-unit recommended):
- checkPer week: 7 syringes (1/day)
- check16 weeks: 112 syringes (recommend ~120 with extras)
Bacteriostatic Water (10 mL bottles): Use 2.0 mL per vial for reconstitution.
- check16 weeks (1 vial): 2 mL → 1 × 10 mL bottle
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer week: 14 swabs (2/day)
- check16 weeks: 224 swabs → recommend 3 × 100-count boxes
Mechanism of Action (MOA)
The Khavinson bioregulator model proposes that ultra-short peptides such as EDL (Ovagen), KE (Vilon), AED (Endoluten/Epitalon family), and KEDA (Livagen) penetrate cell and nuclear membranes through a combination of passive diffusion and PEPT1/PEPT2-mediated transport, then form complementary hydrogen bonds with specific 3- to 6-nucleotide sequences in gene promoter regions [3][6]. Because aging is accompanied by loss of CpG methylation in many tissues, age-exposed DNA becomes more accessible to peptide binding, providing a tissue-specific re-activation of transcription programs that have been silenced. For Ovagen, the target organ is the liver, and reported transcriptional effects include upregulation of albumin, transferrin, cytochrome P450 enzymes, and antioxidant response element-driven genes such as NQO1 and HO-1 [4]. Although there is no published receptor binding profile, no measurable plasma half-life (the peptide is rapidly hydrolyzed), and no defined Cmax in conventional pharmacokinetic terms, Khavinson's group has argued that the biological effect derives from a small fraction of intact peptide reaching the nucleus and the rest acting as conventional amino acid substrate. The most common research route is oral capsules containing approximately 200 mcg of the tripeptide per dose, although a parenteral formulation analogous to other Khavinson cytomedins exists in Russian clinical practice. Studies typically use a 20- to 30-day course at 1 to 2 capsules twice daily, with cycles repeated every 4 to 6 months. Common research uses include chronic hepatitis C and B with elevated transaminases, alcoholic and non-alcoholic fatty liver disease in early-stage observational studies, drug-induced hepatotoxicity recovery (most commonly in oncology supportive care contexts), and general anti-aging protocols where Ovagen is stacked with other Khavinson peptides such as Vladonix (immune), Endoluten (pineal), and Cerluten (brain) for systemic bioregulation. Downstream cellular effects described in preclinical work include increased mitotic index in hepatocytes, restoration of ATP/AMP ratios in aged rodent liver, and reduced oxidative DNA damage measured by 8-OHdG. The Khavinson program has logged over 800 publications on short peptides, but the specific human randomized controlled trial dataset for Ovagen as an isolated molecule is sparse and largely confined to Russian journals; closely related work on Livagen (KEDA) in cultured rat hepatocytes showed a roughly 2-fold increase in protein synthesis in cells from old animals, providing the strongest mechanistic anchor for Ovagen's claimed hepatoprotective effect [5]. Stacking with other Khavinson cytogens including Vladonix (thymus, immune), Endoluten (pineal, melatonin axis), Cerluten (brain), and Ventfort (vascular endothelium) is common in Russian anti-aging research protocols on the rationale that simultaneous tissue-specific modulation across multiple organ systems may compound the proposed gene-reactivation effects. Cycling discipline (20 to 30 days on, 4 to 6 months off) is intended to avoid presumed receptor desensitization and to permit interim laboratory monitoring of liver function tests (ALT, AST, GGT, bilirubin, albumin) before and after each cycle. Russian longitudinal cohort observations using multi-peptide stacks have suggested reductions in biological age estimates of 1 to 2 years over 6 to 12 months of cycled use, though these observations lack blinding, control comparators, and standardized endpoint definitions consistent with Western evidence standards.
Clinical Trial Efficacy Highlights
- starIn rat models of carbon tetrachloride-induced toxic hepatitis, oral administration of EDL tripeptide for 14 days reduced ALT and AST elevations by approximately 35 to 50 percent compared with controls and accelerated normalization of hepatic histology [4].
- starKhavinson and colleagues have documented in cultured hepatocyte studies that EDL-type peptides increase tritiated thymidine incorporation and total protein synthesis preferentially in cells from older animals, consistent with an age-dependent gene reactivation mechanism [5].
- starA small open-label Russian study in patients with chronic viral hepatitis reported decreases in serum transaminases and improvements in subjective fatigue scores after a 20-day course of Ovagen capsules, although the study lacked placebo control and used non-standardized outcome instruments [1].
- starIn rodent models of alcohol-induced steatosis, EDL co-administration reduced hepatic triglyceride accumulation, increased glutathione content, and attenuated upregulation of inflammatory cytokines IL-6 and TNF-alpha in liver tissue [4].
- starKhavinson's broader bioregulator program has reported in elderly cohorts that multi-peptide cycles including liver-targeted peptides correlate with biological age markers improving by 1 to 2 years over a 6- to 12-month observation window, but methodological limitations preclude causal attribution to Ovagen specifically [6].
- starPharmacokinetic modeling of orally administered short peptides suggests that intact EDL reaches systemic circulation in extremely low quantities; the proposed mechanism therefore relies on local intestinal absorption, portal venous delivery to the liver, and high-affinity nuclear binding rather than conventional systemic exposure [3].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningAcross the published Khavinson literature spanning decades of clinical use in Russia, Ovagen and other short-peptide bioregulators are described as having no serious adverse events, no allergic reactions of significance, and no observed toxicity at multiples of the clinical dose.
- warningHowever, no FDA-grade toxicology dossier, no good-laboratory-practice safety pharmacology, and no controlled drug-interaction studies have been published, so the safety claim relies on observational data of variable quality.
- warningTheoretical concerns include altered gene expression in non-target tissues if peptide binding is not as specific as proposed, particularly in patients with active hepatic malignancy where pro-proliferative signaling could be undesirable.
- warningBecause Ovagen is sometimes formulated with carrier proteins or animal-derived excipients, individuals with bovine protein allergy should review the specific product composition; pure synthetic EDL would not pose this risk.
- warningMild gastrointestinal symptoms such as transient nausea or bloating have been described anecdotally with high-dose oral courses but are not consistently reported in published studies.
- warningUse in pregnancy, lactation, and pediatric populations has not been studied; standard Khavinson program guidance excludes these populations from peptide bioregulator protocols.
- warningDrug-drug interactions are theoretically minimal because the peptide is hydrolyzed by intestinal peptidases, but the lack of CYP450 interaction data means that polypharmacy patients should consider monitoring liver enzymes during initial cycles.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical Ovagen dosage?expand_more
Standard Khavinson protocols use 1 to 2 oral capsules (approximately 200 mcg EDL per capsule) twice daily for a 20- to 30-day course, with cycles repeated every 4 to 6 months. Higher doses have not been formally evaluated in published clinical studies.
How is Ovagen used in research protocols?expand_more
Research applications focus on hepatic recovery models including chronic viral hepatitis, drug-induced hepatotoxicity, and fatty liver disease. Outcome measures typically include serum transaminases, albumin, and bilirubin, sometimes supplemented by FibroScan or fibrosis biomarker panels.
Can Ovagen be combined with other peptides?expand_more
Within the Khavinson framework, Ovagen is commonly stacked with Vladonix (thymus/immune), Endoluten (pineal), Cerluten (brain), and Ventfort (vascular) for systemic bioregulation. No formal pharmacokinetic interaction studies exist, and stacking is based on tissue-specific mechanism rather than synergy data.
What are the side effects of Ovagen?expand_more
The published literature describes essentially no serious adverse events, with rare mild gastrointestinal symptoms. However, the absence of modern toxicology and drug-interaction data means that safety is supported primarily by observational use in Russia rather than rigorous controlled trials.
Is Ovagen FDA approved?expand_more
No. Ovagen is not approved by the FDA, EMA, or other major Western regulators and is not authorized as a drug, dietary supplement with structure-function claims, or medical food. It is used only in unapproved research contexts and in Russian clinical practice.
Academic References & Study Citations
Khavinson VK. Peptides and ageing. Neuroendocrinol Lett. 2002;23 Suppl 3:11-144. View Scientific Paper →
Khavinson VK, Linkova NS, Tarnovskaya SI. Short peptides regulate gene expression. Bull Exp Biol Med. 2016;162(2):288-292. View Scientific Paper →
Khavinson VK, Solovyev AY, Tarnovskaya SI, Lin'kova NS. Mechanism of biological activity of short peptides: cell penetration and epigenetic regulation of gene expression. Biol Bull Rev. 2013;3(6):451-455. View Scientific Paper →
Khavinson VK, Malinin VV. Gerontological aspects of genome peptide regulation. Karger; 2005. ISBN 3-8055-7975-1. View Scientific Paper →
Anisimov VN, Khavinson VK. Peptide bioregulation of aging: results and prospects. Biogerontology. 2010;11(2):139-149. View Scientific Paper →
Khavinson VK, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide regulation of gene expression: a systematic review. Molecules. 2021;26(22):7053. View Scientific Paper →
Korkushko OV, Khavinson VK, Shatilo VB, Antonyk-Sheglova IA. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bull Exp Biol Med. 2011;151(3):366-369. View Scientific Paper →
Khavinson V, Linkova N, Dyatlova A, Kantemirova R, Kozlov K. Peptides: prolongation of life of model organisms. Cells. 2020;9(7):1714. View Scientific Paper →